1/2/2025 | BKCVDDEMIGPV | Market Commentary: Junk primary market stays shuttered; secondary market launches new year on firm footing
|
10/8/2024 | BKCVDDEMIGPV | Market Commentary: Cleveland-Cliffs drives by junkland; Patrick Industries weaker; Caesars improves
|
10/7/2024 | BKCVDDEMIGPV | Market Commentary: Primary resumes active pace; recent issues weaken in soft secondary; Caesars falls
|
10/3/2024 | BKCVDDEMIGPV | Market Commentary: European junk primary active; Belron outperforms; Caesars flat; funds add $2.2 billion
|
1/30/2024 | BKCVDDEMIGPV | Market Commentary: Junk primary clears $5.45 billion; new paper dominates secondary; Shelf Drilling tumbles
|
1/25/2024 | BKCVDDEMIGPV | Market Commentary: Junk: NGL, Talos price; Rakuten joins calendar; Caesars, Freedom Mortgage, Merlin strong
|
1/27/2023 | BKCVDDEMIGPV | Market Commentary: Evergreen returns some gains; Caesars’ junk bonds still active; Medical Properties falls
|
1/25/2023 | BKCVDDEMIGPV | Market Commentary: Crescent Energy brings drive-by; Mauser on HY deck, existing notes up; Norwegian adds
|
1/24/2023 | BKCVDDEMIGPV | Market Commentary: New junk paper: Caesars, PRA Group gain in heavy volume; Garda holds strong premium
|
1/23/2023 | BKCVDDEMIGPV | Market Commentary: Caesars Entertainment, PRA Group, Garda price; Savers Value on deck
|
11/18/2022 | BKCVDDHY | S&P ups Caesars Resorts
|
12/17/2021 | BKCVDDEMIGPV | Market Commentary: Junkland: no new deals; reopening trade falters: AMC, Carnival, Caesars under pressure
|
9/15/2021 | BKCVDDEMIGPV | Market Commentary: Junk primary raises $2.1 billion; Coinbase disappoints; Caesars up; Wynn under pressure
|
9/13/2021 | BKCVDDEMIGPV | Market Commentary: Primary prices $3.2 billion; forward calendar grows; Caesars, PGT on a 101-handle
|
9/10/2021 | BKCVDDEMIGPV | Market Commentary: Caesars, PGT price; megadeals on deck; Allegheny, SNF, RLJ, Ball at a premium
|
9/10/2021 | BKDDHY | Moody's assigns Caesars Caa1
|
9/10/2021 | BKDDHY | S&P gives Caesars notes CCC+
|
8/12/2021 | BKDDHY | Moody's stabilizes Caesars view
|